Metastatic Castrate-Resistant Prostate Cancer

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

Initial study results may be available as soon as the first half of 2026.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.